Bacillus subtilis strain with strong inhibition of enteropathogenic and foodborne pathogenic bacteria
Pathogens present a major healthcare and economic burden. Amongst the major pathogens causing diarrhea are Listeria spp., Staphylococcus spp., Salmonella spp., E. coli, and Campylobacter spp. Campylobacteriosis is the most frequently reported bacterial foodborne infection transmitted to humans, both in the European Union (EU) and the United States (US), and its major cause is Campylobacter jejuni. Most of C. jejuni infections have been associated with poultry meat and the poultry industry, which is also a major source of antibiotic resistant C. jejuni strains, as more than 50% of isolates from poultry are now resistant to at least one antibiotic.
Description of the Invention
Bacillus subtilis strain PS-216 has been shown to have strong inhibitory activity against enteropathogenic and/or foodborne pathogenic bacteria, such as Campylobacter jejuni. Particularly, our innovative product uses the Bacillus subtilis strain PS-216 for the preparation of food compositions and probiotic compositions. Probiotics can have beneficial effects on poultry, such as growth promotion, immunomodulation, and inhibition of pathogens. Bacillus subtilis strain PS-216 has the ability to greatly reduce the growth and biofilm formation of pathogens and C. jejuni colonization in broilers when compared to other B. subtilis strains. Moreover, the treatment of broilers with B. subtilis PS-216 results in an increased weight of broilers.
- Growth and biofilm formation reduction of pathogens
- Reduction of C. jejuni colonization in poultry
- Increased weight gain of broilers